ImmuPharma PLC - Asset Resilience Ratio

Latest as of December 2023: 0.00%

ImmuPharma PLC (IMM) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read ImmuPharma PLC (IMM) total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

GBX-1.00

≈ $-0.00 USD Cash + Short-term Investments

Total Assets

GBX2.72 Million

≈ $331.12 USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2022)

This chart shows how ImmuPharma PLC's Asset Resilience Ratio has changed over time. See ImmuPharma PLC shareholders equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down ImmuPharma PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ImmuPharma PLC (IMM) total market value.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	GBX0.00	0%
Short-term Investments	GBX-1.00	-0.0%
Total Liquid Assets	GBX-1.00	0.00%

Asset Resilience Insights

Limited Liquidity: ImmuPharma PLC maintains only 0.00% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

ImmuPharma PLC Industry Peers by Asset Resilience Ratio

Compare ImmuPharma PLC's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Royalty Pharma Plc NASDAQ:RPRX	Biotechnology	0.10%
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	3.28%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	4.52%
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	Biotechnology	35.56%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Jiangsu Aidea Pharmaceutical Co Ltd SHG:688488	Biotechnology	4.35%

Annual Asset Resilience Ratio for ImmuPharma PLC (2016–2022)

The table below shows the annual Asset Resilience Ratio data for ImmuPharma PLC.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2022-12-31	-2.08%	GBX-82.56K ≈ $-10.05	GBX3.97 Million ≈ $483.61	+4.68pp
2021-12-31	-6.76%	GBX-405.49K ≈ $-49.34	GBX6.00 Million ≈ $729.76	-5.16pp
2020-12-31	-1.60%	GBX-174.49K ≈ $-21.23	GBX10.92 Million ≈ $1.33K	+12.94pp
2019-12-31	-14.53%	GBX-843.15K ≈ $-102.59	GBX5.80 Million ≈ $705.82	-37.71pp
2016-12-31	23.17%	GBX1.55 Million ≈ $189.18	GBX6.71 Million ≈ $816.39	--

pp = percentage points

About ImmuPharma PLC

LSE:IMM UK Biotechnology

Market Cap

$253.23K

GBX2.08 Billion GBX

Market Cap Rank

#30766 Global

#997 in UK

Share Price

GBX4.14

Change (1 day)

+2.22%

52-Week Range

GBX1.50 - GBX17.60

All Time High

GBX190.00